NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is making strides in the research and development of cardiometabolic disease treatments with the full data from their ROSE2 trial set to be presented at the upcoming National Lipid Association Scientific Sessions.
Their promising clinical-stage fixed dose combination of obicetrapib 10 mg and ezetimibe 10 mg is gearing up to launch a definitive bioequivalence trial and a Phase 3 safety and efficacy trial in the second half of 2023. It’s a thrilling time for NewAmsterdam and their potential to revolutionize cardiometabolic treatments is worth watching!
ROSE2: The Impressive LDL-C Reduction of a Reinforced Statin Therapy Combination. Results from the ROSE2 Trial (NCT05266586) Show the Effects of Obicetrapib and Ezetimibe on High Intensity Statin Use.
Join us on Saturday, June 3, 2023 for our exciting Late-Breaker Session at the Omni Atlanta Hotel at CNN Center! Don’t miss this opportunity to learn the latest in the industry and gain insight from the experts in the field. Get ready to engage in the discussion and exchange of ideas—12:00 P.M. ET is the time to be there.
Investor and Analyst Conference Call and Live Webcast
Join us for a live webcast on Monday, June 5th at 8:00 a.m. ET and hear from Robert Rosenson, Professor of Medicine and Director of Cardiometabolic Disorders at the Icahn School of Medicine at Mount Sinai, as he presents the full data and findings from the ROSE2 Study. Invest in the future and get the insights you need to make informed decisions at NewAmsterdam’s exclusive conference call.
Participants may register for the conference call here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
The archived webcast will be available on NewAmsterdam’s website approximately two hours after the conference call and will be available for at least 30 days following the live event.
NewAmsterdam, a clinical-stage biopharmaceutical company dedicated to improving patient care through its innovative obicetrapib drug, recently closed a business combination with FLAC and is now ready to make its mark on the healthcare industry. Their ROSE Phase 2b trial showed that obicetrapib 10 mg reduced LDL-C levels by a median of 51%, versus a 7% reduction in the placebo arm, in patients with high-risk cardiovascular diseases taking high-intensity statins.
Coupled with results from the ROSE2 trial showing a 59% median reduction in cholesterol levels when used in combination with ezetimibe, obicetrapib appears to be a promising candidate for LDL-C lowering therapy. Having secured an exclusive licensing agreement with the Menarini Group for commercialization in Europe, as well as rights to develop obicetrapib for additional diseases, NewAmsterdam promises to be an exciting future player in the world of cardiometabolic medicine.
This document contains forward-looking statements which predict the future events or trends that are related to the Company’s business and strategic plans, clinical trials, data announcements, and regulatory approvals. These are based on assumptions and expectations of the Company’s management, and any discrepancies between the actual results and the statements made can be attributed to various risks and uncertainties.
These risks include changes in global market, political and legal conditions; product candidate approvals and other business-related milestones, competition, ability to find qualified personnel, and the impacts of COVID-19. Additionally, the Company also may face other risks that are not immediately known. Therefore, readers should not rely solely on these forward-looking statements as they may differ from actual results due to these risks.